Skip to content

Evaluation of the clinical efficacy of Yi Xin prescription in the treatment of heart failure with preserved ejection fraction in the type of qi deficiency and blood stasis

Evaluation of the clinical efficacy of Yi Xin prescription in the treatment of heart failure with preserved ejection fraction in the type of qi deficiency and blood stasis

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400085509
Enrollment
Unknown
Registered
2024-06-11
Start date
2024-06-15
Completion date
Unknown
Last updated
2024-07-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Heart failure with preserved ejection fraction in the type of qi deficiency and blood stasis

Interventions

Control group:Standardized treatment + placebo pellets

Sponsors

Yueyang Hospital of Integrated Traditional Chinese Medicien and Western Medicine, Shanghai University of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
35 Years to 85 Years

Inclusion criteria

Inclusion criteria: (1) 35 years old = age = 85 years old, gender is not limited; (2) Stabilized for more than 1 month after volume management; (3) Outpatients or hospitalized patients who meet the diagnosis of heart failure with preserved ejection fraction; (4) Clinical diagnosis of Qi deficiency and blood stasis in Chinese medicine; (5) Those who voluntarily participate in the study and sign the informed consent form.

Exclusion criteria

Exclusion criteria: (1) Patients with acute infarction, acute heart failure, cardiogenic shock, uncontrollable malignant arrhythmias, constrictive pericarditis, unrepaired valvular disease, complete atrioventricular block, pericardial tamponade, and obvious infections; (2) Patients with right heart failure, acute pulmonary edema, or acute hemodynamic disturbances due to pulmonary disease; (3) Patients with primary pulmonary hypertension, secondary severe pulmonary hypertension and combined chronic obstructive pulmonary disease; (4) Patients with severe uncontrolled hypertension (systolic blood pressure = 180 mmHg or diastolic blood pressure = 110 mmHg); (5) Patients with combined heart, liver, kidney, hematopoietic and metabolic systems and other serious primary diseases, malignant tumors, jaundice, liver and kidney insufficiency; (6) Women who are planning to become pregnant, pregnant or breastfeeding; (7) Patients who have participated or are participating in other clinical studies within 1 month prior to enrollment or who are allergic to Yi Xin prescription related traditional Chinese medicine.

Design outcomes

Primary

MeasureTime frame
Cardiac function classification;

Secondary

MeasureTime frame
B-type natriuretic peptide precursor;Cardiac ultrasound;Growth-stimulated expression of gene 2 protein;Six-minute walk test;Traditional Chinese Medicine Syndrome Score Scale;

Countries

China

Contacts

Public ContactFu Deyu

Yueyang Hospital of Integrated Traditional Chinese Medicine and Western Medicine, Shanghai University of Traditional Chinese Medicine

fdy650@126.com+86 151 5625 8536

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026